Chu, Q.S.C.

patient erlotinib cancer study toxicity skin toxicity 150 mg response grade escalation treatment trial activity level month phase dose escalation anticancer activity erlotinib doses cutsem factor disease range oncol intrapatient dose escalation british journal 2.0 result growth epidermal nsclc receptor number research anticancer intrapatient tumour table non-small cancer institute non-small-cell lung cancer inhibitor erlotinib 150 mg metastatic colorectal cancer dose escalation scheme van cutsem disease progression exposure minocycline status objective colorectal british journal pk parameters non-cutaneous dlt drug exposure egfr inhibitors erlotinib dose smoker dosing-to-rash parameter perez-soler severity concentration sample target relationship mutation 200 mg phase iii trial unselected patient population clark g pharmacokinetic grade 3 anorexia erlotinib exposure dose escalation strategy population erlotinib dose level function